A handful of recent biotech-device company deals have highlighted the potential of drug-device convergence as natural extensions of the ever-popular repurposing and drug delivery models espoused by investors aiming to reduce the risks associated with drug discovery. Venture capitalists are eager to get in on the game, but drug and device hybrid business models are few and far between. True convergence start-ups remain thin on the ground, a fact VCs say reflects the additive nature of drug risk and device risk.
by Christopher Morrison
Drug-eluting stents are the Reese's Peanut Butter Cups of the health care world. While it might not have been obvious...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Deal Snapshot: Hengrui makes its third potential billion-dollar licensing deal of 2025, this time sending rights to Phase III hypertrophic cardiomyopathy drug HRS-1893 to Braveheart.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.
R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.
The OX40 ligand-targeting drug’s efficacy is seen as light compared with existing therapies.
Zydus's saroglitazar beat both Gilead’s Livdelzi and Ipsen’s Iqirvo on biochemical response in topline results from a Phase IIb/III trial in primary biliary cholangitis, but subtle differences in definitions, data on pruritus or itching and other factors could be key to approval and adoption.
R&D leaders highlighted two potential first-in-class assets during a therapeutic area overview, but regulatory filings remain years out.
